Ovarian Cancer

Ovarian cancer expert Kelly McCann, MD, PhD, discusses the process of DNA damage and repair, resistance to PARP inhibitors, and rational combination strategies to overcome resistance.

In an interview with&nbsp;<em>Targeted Oncology</em>, Panagiotis A.&nbsp; Konstantinopoulos, MD, director of Translational Research, Gynecologic Oncology Program at Dana-Farber Cancer Institute, and associate professor of medicine at Harvard Medical School, discussed the findings from the TOPACIO trial for patients with platinum-sensitive ovarian cancer. He also highlights the outlook for immunotherapy in gynecologic cancers and what the next steps are moving forward.

Shannon Westin, MD, MPH, recently explained the treatment considerations and decisions she makes when treating patients with ovarian cancer. Westin explained her treatment decisions based on 2 case scenarios during a <em>Targeted Oncology</em> live case-based peer perspectives presentation.

General Cancer

The FDA approved several indications in the month of June, including venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL), the combination of binimetinib (Mektovi) plus encorafenib (Braftovi) in melanoma, and bevacizumab (Avastin) in ovarian cancer. The FDA also accelerated approvals for pembrolizumab (Keytruda) in cervical cancer and in primary mediastinal large B-cell lymphoma, while also granting a priority review to glasdegib for acute myeloid leukemia.

In findings from the&nbsp;randomized phase III SOLO-1 trial, olaparib (Lynparza) tablets&nbsp;reduced the risk of disease progression or death compared with placebo as frontline maintenance therapy for women with <em>BRCA</em>-positive advanced ovarian cancer.

Christa Dominick, MD, a gynecologic oncology fellow at University Hospitals, discusses the rationale behind this trial and the results. She also highlights her plans moving forward with other trials involving the cowpea mosaic virus in ovarian cancer.<br /> &nbsp;